{"name":"Qing-Lei Zeng","slug":"qing-lei-zeng","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Entecavir + Pegylated interferon α-2b","genericName":"Entecavir + Pegylated interferon α-2b","slug":"entecavir-pegylated-interferon-2b","indication":"Chronic hepatitis B infection","status":"marketed"}]}],"pipeline":[{"name":"Entecavir + Pegylated interferon α-2b","genericName":"Entecavir + Pegylated interferon α-2b","slug":"entecavir-pegylated-interferon-2b","phase":"marketed","mechanism":"This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells.","indications":["Chronic hepatitis B infection"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}